Torax Medical's Linx completed its Caliber trial and found it was more effective than omeprazole in controlling regurgitation and improving quality of life for patients with gastroesophageal reflux disease.
Researchers conducted a multicenter randomized controlled trial comparing Linx to omeprazole in 150 patients with regurgitation. Patients either took omeprazole twice daily or Linx. The primary endpoint was how it affected regurgitation.
Here's what you should know.
1. Approximately 92.6 percent of patients treated with Linx achieved the primary endpoint success criteria versus 6.8 percent who researchers treated with omeprazole.
2. Exactly 88.9 percent of patients treated with Linx had significant improvement in quality of life. Quality of life increased for only 6.8 percent of patients treated with omeprazole
3. Linx restored normal reflux levels in 92 percent of Linx patients while omeprazole restored normal levels in 36 percent of patients.
Researchers are following the patients for a year after the treatment. Torax expects additional results in late 2017.
Researchers presented the study at Digestive Disease Week, May 6 through May 9 in Chicago.